혈관신생 어세이 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

Angiogenesis Assay Market

The future of the global angiogenesis assay market looks promising with opportunities in the academic institution, pharmaceutical company, biotechnology company, and contract research organization markets. The global angiogenesis assay market is expected to reach an estimated $6 billion by 2035 from $3 billion in 2027 with a CAGR of 6.4% from 2027 to 2035. The major drivers for this market are the increasing focus on cancer research, the rising demand for drug discovery applications, and the growing adoption of personalized medicine approaches.

• Lucintel forecasts that, within the product type category, kits is expected to witness the highest growth over the forecast period due to the use of ready-to-use kits provides many benefits such as convenience and standardization.
• Within the end use category, academic institutions is expected to witness the highest growth over the forecast period due to funding for academic research on angiogenesis has been strong.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to biotechnology research, in general, has strong research funding and research infrastructure.

Emerging Trends in Angiogenesis Assay Market

Between 2025 and 2027, the angiogenesis assay market will transition from basic endothelial cell-based assays to more complex predictive assays. The pharmaceutical industry is interested in endothelial cell assays to demonstrate efficacy in various indications such as oncology and ophthalmology and to promote wound healing. Lucintel also expects changes in the market to facilitate the integration of 3D models and other advanced cellular and assay automation to enhance the translation of in vitro to in vivo data.

• Advances in Cellular and Molecular Biology: In 2025, further advances in 3D cell culture and differentiation are expected to allow for the generation of organoids and other complex structures. These may replace the current in vitro cell-based assays.
• Image Analysis and Artificial Intelligence (AI): In the same timeframe, integration of AI in various aspects of image analysis and interpretation to assess vessel density, morphology and other parameters is expected. This will further improve the throughput of assays and facilitate analysis across multiple sites.
• Assay Automation and Miniaturization: Further integration of automation and miniaturization will provide for high-throughput endothelial cell assays that may be performed in large screens by a number of researchers, thereby reducing the cost of each assay.
• Translational Testing: The use of primary human cells, patient materials and disease-relevant endothelial cells became more prevalent in 2025, and use of immortalized cell lines diminished. The introduction of human cells should improve the selection of diagnostic markers and enhance anti-angiogenic drug development.
• Standardization and QA: Variation in the outcome of assays between different laboratories prompted the development of more rigorous standards and control materials. The active participation of the pharmaceutical industry in the development of standardized in vitro assays to distinguish between productive and unproductive research efforts is of great importance and will ultimately impact the selection of the in vitro assays used in the pharmaceutical industry.

The emphasis of researchers is on the development of biologically more relevant assays. Companies that integrate realism in cell culture and assay development, along with automation and computer simulation, will be competitive. Thus far, the focus has been on the research market; however, the development of specialized assays for hard-to-study diseases will continue. Improved data quality will impact research prioritization.

Recent Developments in the Angiogenesis Assay Market

Angiogenesis assays are used to assess blood vessel formation and are beneficial in the evaluation of various anticancer and antiangiogenic agents. Drug development is transitioning to more advanced models of cell culture away from conventional 2D cell culture. As a result, increased demand for angiogenesis assays is anticipated. Further, stringent regulations for clinical trial approvals are anticipated to bolster the demand for angiogenesis assays. Among other factors, Lucintel expects automation and standardization of angiogenesis assays will create market opportunities.

• Adoption of 3D Models: A peer-reviewed article published in January 2025, indicated that vascularized organoids replaced the use of animals in pharmaceutical safety assessment by 30%. The increased demand for advanced models that resemble physiological tissues will further catalyze the use of premium angiogenesis assays.
• Investments in Automation: In March 2025, a leading company in laboratory automation launched a 384-well microplate-based automated liquid handling system designed for angiogenesis assays. The system integrated numerous reagents and assay consumables and will stimulate the market for integrated automation systems.
• Partnerships for Imaging and Assessment: In June 2025, a partnership was formed to integrate time-lapse microscopy and four-dimensional imaging for assessment of vascular formation. Such collaborations will foster the use of real-time, quantitative assessments for angiogenesis in research and clinical laboratories.
• Validation of Organoids: A multicenter validation study, conducted in September 2025, compared three different types of human endothelial cell assay formats. The results of this study will help determine the level of standardization in these formats, and help clients make informed decisions on large-scale purchases.
• Reagent Growth: In February 2026, a company launched two Matrigel alternatives in the angiogenesis assay field. Due to consistency and traceability concerns, defined extracellular matrices will progressively replace K Satory Matrigel in primary research and quality controls within the next 3-5 years.

Because research requirements will eventually favor defined extracellular matrices, the companies that will prosper in this sector will be those who have the ability to integrate biologically more accurate in vitro models with continuous control and analysis. The market will be dominated by pharma and CRO clients. Reproducibility will replace novelty in the focus of the assay development.

Strategic Growth Opportunities in the Angiogenesis Assay Market

The angiogenesis assay market is expected to change during the 2024-2026 time frame, with academic screening closing and covered markets opening. The pharmaceutical industry is increasingly interested in surrogate markers of anti-cancer drug efficacy. Lucintel is equally interested in these trends due to ongoing investments in personalized medicine.

• The Use of Organoids in Oncology: Assays based on patient tumor organoids have the potential to improve the selection of cancer therapies and increase the level of evidence in the translation of preclinical research to the clinic. The increased demand for better predictive preclinical assays was reflected in the 2024 FDA drug approvals. Anticipation of customer requirements will result in more sophisticated assays in the marketplace.
• Automation: The use of automation in cell culture, assay, and analysis will result in increased throughput and standardization of screening. Major contract research organizations increased the number of supported assays from 96-well to 384-well formats. Automation will result in fewer employees being directly involved in research.
• Organ-on-chip: The use of organ-on-chip technologies in the pharmaceutical and medical device sectors will increase as the demand for human cellular and tissue based assays (hCTPAs) increases. The 2025 FDA Modernization Act further facilitated the use of alternative animal-based methods in the pharmaceutical industry.
• Contract Research Services: Contract Research Organizations (CROs) offer services such as assay design and screening as well as image analysis and documentation to biotech companies that lack the capabilities. In 2025, the global spending on pharmaceutical R&D is projected to exceed $200 billion. The demand for contract research will continue. The cost to establish and maintain vascular biology infrastructures will discourage companies from developing the capabilities internally, creating an opportunity for contract research in that area as well.
• Green Assay Kits: Suppliers of reagents and assay kits can improve sustainability of their offerings by eliminating animal components and using recyclable consumables. The EU initiatives to reduce greenhouse gas emissions will continue to increase competition among research laboratories. Similarly, environmental sustainability will become part of the criteria used by researchers to evaluate the supplies they purchase.

These trends are expected to benefit assay kit suppliers by creating recurring revenues. Demand for kits for the study of cancer will continue. Further, the use of organoids and other technologies to study other biological systems will increase. Automation of these systems will improve reproducibility and reduce variability. Finally, while the ability to provide biological relevance of a product will benefit suppliers, the same will be true for other integrative capabilities such as software and services.

Angiogenesis Assay Market Drivers and Challenges

The angiogenesis assay market is poised for growth due to advances in technology, expanding biomedical research, increasing market demands and requirements, and improvement in regulatory standards and guidelines. Moreover, the expanding body of research in oncology, ophthalmology, and cardiovascular fields, as well as in tissue engineering, has increased the need for reliable biomedical assays. Lucintel estimates that advances in assay automation and other methodological improvements will increase the market in the coming years. However, challenges such as biological variability, high costs, and complex assay methodologies hinder the use of angiogenesis assays in general research laboratories.

The factors responsible for driving this market include :

• Increased Research in Oncology: Increased research in oncology has created a need to assess angiogenesis in tumor vasculature, and evaluate the efficacy of anti-angiogenic therapies. It is anticipated that in the next three to five years, the angiogenesis assay market will experience considerable growth, due to the increased need to assess vascular endothelial cell behavior to gain insights into tumor vasculature and other vital components of the tumor microenvironment.
• Improvements in Technology: Ongoing advancements in the fields of 3D cell culture, organoids, microfluidics, imaging and software, and automation are improving angiogenesis assays. In 2025, several labs shifted to 3D matrix-based assays and automated image analysis. In the following years, even more labs are expected to adopt these methods, and the focus of the assays is expected to shift from simple measurements of tube formation to more complex measures of vascular structure and function (e.g. vascular branching and perfusion). Many companies are also developing automated systems to eliminate the need for human interpretation and to integrate systems with artificial intelligence.
• Increased Use in Drug Discovery: The use of angiogenesis assays has expanded to evaluate a wide array of therapeutic modalities (e.g. biologics, small molecules, cell therapies, RNA-based therapies) to evaluate their effects on the vasculature. In 2025, there were several ongoing preclinical programs that evaluated anti-angiogenic and immuno-oncology combinatorial therapies, which created an increased demand for angiogenesis assays. This type of demand will promote the continued refinement of these assays to measure diverse indications (e.g. ischemic conditions, wound healing, and regenerative medicine).
• Decreasing Reliance on Animal Testing: Research organizations will increasingly adopt strategies to reduce reliance on animal testing. During the next three to five years, particular emphasis will be placed on alternative testing strategies to gain accelerated regulatory approval for products. Angiogenesis assays provide opportunities for laboratory studies to replace animal testing. Early angiogenesis assays may help offset the costs of research by filtering out non-product candidates. Research organizations may be more likely to adopt angiogenesis assays if platforms demonstrate positive correlations to in vivo studies and/or other assays.
• Improving The Efficiency of Laboratory Studies: Automation and other advances in laboratory technology will increase researchers' ability to study multiple conditions and variability in a single assay. Manufacturing advances may help reduce the variability in materials and reagents used in laboratory studies. These trends will help ease the restrictions on research staff and increase the overall capacity of laboratories to study various conditions. Suppliers may gain a competitive edge in the market by developing products that integrate automation and help laboratories maintain research equipment within staffing and budgetary constraints.

The challenges facing this market include:

• Biological Variability and Lack of Standardization: The use of different types of cells, differences in the number of times a cell is divided (or passage number), differences in the composition of the extracellular matrix, differences in the type and amount of growth factors, and differences in the conditions of the culture and analysis, lead to a lack of standardization and consistency in the results of assays. Comparative laboratory studies performed in May 2025 showed that even with standardization of several of the above conditions, the assays did not reach reproducibility. It is expected that the above conditions will negatively affect the market during the next three to five years. This situation can delay the acceptance of assays by regulatory agencies. To improve the situation, assay suppliers should standardize systems, assay conditions and controls, and establish inter-laboratory communications.
• Technology and Costs: : There are several high technology systems (e.g., microfluidic systems, organoid systems, and automated systems) that require significant financial and human resources and, therefore, are beyond the means of many laboratories. This situation will probably affect the market during the next three to five years. Equipment and supply costs associated with automated systems for the study of angiogenesis negatively impacted many laboratories during 2025.
• Translational Gaps: Vascular biology encompasses a wide range of factors including the immune system, tissue and organ structure and function, and metabolism. Disease conditions also influence vascular biology. Predicting the behavior of vascular biological systems using in vitro angiogenesis models remains challenging. As of January 2026, it was reported that combinatorial approaches, integrating multiple assay types, were preferred over reliance on angiogenesis assays, to make pivotal decisions in clinical research. The approaches based on integrating multiple assay types are expected to gain broad market acceptance within the next three to five years. This is especially the case if the food and drug administration (FDA) and other similar regulatory agencies ease their acceptance. The main challenges are expected to be the high costs associated with the new technologies and assays, and concerns related to their acceptance. Reproducible and clinically relevant technologies will be preferred.

In the next three to five years, the market for angiogenesis assays is projected to experience positive growth largely due to advanced cell models and automation, especially in the field of oncology. While biological variability limits the broad market adoption, ongoing research is expected to address this concern.

List of Angiogenesis Assay Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies angiogenesis assay market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the angiogenesis assay market companies profiled in this report include-

• Thermo Fisher Scientific
• Merck KGaA
• BD
• Promega Corporation
• Cell Biolabs, Inc.

Angiogenesis Assay Market by Segment

The study includes a forecast for the global angiogenesis assay market by product type, method, application, end use, and region.

Angiogenesis Assay Market by Product Type [Value ($B) from 2019 to 2035]:

• Kits
• Reagents
• Cell Lines
• Microplates
• Instruments

Angiogenesis Assay Market by Method [Value ($B) from 2019 to 2035]:

• In Vivo Assays
• In Vitro Assays
• Ex Vivo Assays
• High-Throughput Screening
• Microscopic Analysis

Angiogenesis Assay Market by Application [Value ($B) from 2019 to 2035]:

• Cancer Research
• Cardiovascular Research
• Ocular Diseases
• Wound Healing
• Developmental Biology

Angiogenesis Assay Market by End Use [Value ($B) from 2019 to 2035]:

• Academic Institutions
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Others

Angiogenesis Assay Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Angiogenesis Assay Market

Lucintel expects that improvements in organoid, translational oncology and advanced cell culture models will create additional opportunities for the angiogenesis assay market. Rising public funds, along with expansion of laboratory infrastructure, are expected to boost demand for endothelial cell and other 3D cell and assay systems during the period from 2025 to 2027. According to Lucintel, these trends have already influenced the pharmaceutical and academic research markets.

• United States: Increased funding for the next five years by the National Institutes of Health (NIH) is expected to facilitate the adoption of assays by pharmaceutical companies. In addition, Bio-Techne and Thermo Fisher Scientific enhanced their offerings for cell and tissue research.
• China: Recent focus on biomedical research, along with the construction of next-generation national laboratories, will not only improve infrastructure and reagents for cell- and assay-based research, but also integrate angiogenesis research.
• Germany: Advanced cell research and bioprocessing continues to thrive in Germany, and in February 2025, Merck KGaA reported a record net sales year in 2024, bringing in €21.0 billion, and announced further expansion of their Life Science business. With continued investment in the business, they are expected to improve their distribution, as well as application and assay development, throughout Europe.
• India: In August 2024, the Indian government announced the BioE3 policy, and the Indian Department of Biotechnology (DBT) allocated more funding in the March 2025 Union Budget, offering further support to bio innovation and translational research. With additional research facilities in India, more vascular biology assays should be made available to the Indian biomedical industry.
• Japan: In December 2024, the Japanese government increased funding for research, including regenerative medicine. With the expected improvement in research and development facilities in Japan, additional assays to study angiogenesis, and other related research in the fields of oncology and pharmaceuticals, should be made available.

Features of the Global Angiogenesis Assay Market

• Market Size Estimates: angiogenesis assay market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: angiogenesis assay market size by various segments, such as by product type, method, application, end use, and region in terms of value ($B).
• Regional Analysis: angiogenesis assay market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different product types, methods, applications, end uses, and regions for the angiogenesis assay market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the angiogenesis assay market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the angiogenesis assay market by product type (kits, reagents, cell lines, microplates, and instruments), method (in vivo assays, in vitro assays, ex vivo assays, high-throughput screening, and microscopic analysis), application (cancer research, cardiovascular research, ocular diseases, wound healing, and developmental biology), end use (academic institutions, pharmaceutical companies, biotechnology companies, contract research organizations, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Angiogenesis Assay Market by Product Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product Type
• 4.3 Kits : Trends and Forecast 2019 to 2035
• 4.4 Reagents : Trends and Forecast 2019 to 2035
• 4.5 Cell Lines : Trends and Forecast 2019 to 2035
• 4.6 Microplates : Trends and Forecast 2019 to 2035
• 4.7 Instruments : Trends and Forecast 2019 to 2035

5. Global Angiogenesis Assay Market by Method

• 5.1 Overview
• 5.2 Attractiveness Analysis by Method
• 5.3 In Vivo Assays : Trends and Forecast 2019 to 2035
• 5.4 In Vitro Assays : Trends and Forecast 2019 to 2035
• 5.5 Ex Vivo Assays : Trends and Forecast 2019 to 2035
• 5.6 High-Throughput Screening : Trends and Forecast 2019 to 2035
• 5.7 Microscopic Analysis : Trends and Forecast 2019 to 2035

6. Global Angiogenesis Assay Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Cancer Research : Trends and Forecast 2019 to 2035
• 6.4 Cardiovascular Research : Trends and Forecast 2019 to 2035
• 6.5 Ocular Diseases : Trends and Forecast 2019 to 2035
• 6.6 Wound Healing : Trends and Forecast 2019 to 2035
• 6.7 Developmental Biology : Trends and Forecast 2019 to 2035

7. Global Angiogenesis Assay Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Academic Institutions : Trends and Forecast 2019 to 2035
• 7.4 Pharmaceutical Companies : Trends and Forecast 2019 to 2035
• 7.5 Biotechnology Companies : Trends and Forecast 2019 to 2035
• 7.6 Contract Research Organizations : Trends and Forecast 2019 to 2035
• 7.7 Others : Trends and Forecast 2019 to 2035

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Angiogenesis Assay Market by Region

9. North American Angiogenesis Assay Market

• 9.1 Overview
• 9.2 North American Angiogenesis Assay Market by Product Type
• 9.3 North American Angiogenesis Assay Market by End Use
• 9.4 The United States Angiogenesis Assay Market
• 9.5 Canadian Angiogenesis Assay Market
• 9.6 Mexican Angiogenesis Assay Market

10. European Angiogenesis Assay Market

• 10.1 Overview
• 10.2 European Angiogenesis Assay Market by Product Type
• 10.3 European Angiogenesis Assay Market by End Use
• 10.4 German Angiogenesis Assay Market
• 10.5 French Angiogenesis Assay Market
• 10.6 Italian Angiogenesis Assay Market
• 10.7 Spanish Angiogenesis Assay Market
• 10.8 The United Kingdom Angiogenesis Assay Market

11. APAC Angiogenesis Assay Market

• 11.1 Overview
• 11.2 APAC Angiogenesis Assay Market by Product Type
• 11.3 APAC Angiogenesis Assay Market by End Use
• 11.4 Chinese Angiogenesis Assay Market
• 11.5 Indian Angiogenesis Assay Market
• 11.6 Japanese Angiogenesis Assay Market
• 11.7 South Korean Angiogenesis Assay Market
• 11.8 Indonesian Angiogenesis Assay Market

12. ROW Angiogenesis Assay Market

• 12.1 Overview
• 12.2 ROW Angiogenesis Assay Market by Product Type
• 12.3 ROW Angiogenesis Assay Market by End Use
• 12.4 Middle Eastern Angiogenesis Assay Market
• 12.5 South American Angiogenesis Assay Market
• 12.6 African Angiogenesis Assay Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Product Type
  • 14.2.2 Growth Opportunity by Method
  • 14.2.3 Growth Opportunity by Application
  • 14.2.4 Growth Opportunity by End Use
• 14.3 Emerging Trends in the Global Angiogenesis Assay Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 Thermo Fisher Scientific
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Merck KGaA
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 BD
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Promega Corporation
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Cell Biolabs, Inc.
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Abcam plc
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 R&D Systems
  • Company Overview
  • Angiogenesis Assay Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us